8-K: Surgery Partners Reports Strong Q2 2025 Growth

Surgery Partners, Inc. announced strong second quarter 2025 financial results, reaffirming its full-year 2025 revenue and Adjusted EBITDA guidance.

Summary

• Revenue for the second quarter of 2025 increased 8.4% year-over-year to $826.2 million.
• Same-facility revenues grew by 5.1% for the second quarter, driven by a 3.4% increase in same-facility cases and a 1.6% increase in revenue per case.
• Net loss attributable to Surgery Partners, Inc. was $2.5 million for the second quarter of 2025.
• Adjusted EBITDA increased 9.0% to $129.0 million for the second quarter of 2025.
• For the full year 2025, revenue guidance was reaffirmed in the range of $3.30 billion to $3.45 billion.
• Full year 2025 Adjusted EBITDA guidance was reaffirmed in the range of $555 million to $565 million.
• Year-to-date 2025 revenues increased 8.3% to $1,602.2 million, with Adjusted EBITDA at $232.9 million.
• Cash and cash equivalents stood at $250.1 million as of June 30, 2025, with $394.9 million of borrowing capacity under its revolving credit facility.
• Cash flows from operating activities for Q2 2025 were $81.3 million, a decrease from $82.8 million in Q2 2024, primarily due to higher cash interest payments.
• The ratio of total net debt to EBITDA, as calculated under the credit agreement, was approximately 4.1x at the end of the second quarter of 2025.

Sentiment

Score: 7

Explanation: The company reported strong revenue and Adjusted EBITDA growth, reaffirmed full-year guidance, and is actively pursuing portfolio optimization. However, it reported a net loss and a decrease in operating cash flow, primarily due to higher interest payments, and maintains a relatively high debt leverage. The overall tone is positive, focusing on operational strength and future growth.

Positives

• Reported strong revenue growth of 8.4% for Q2 2025 and 8.3% year-to-date 2025.
• Achieved a 9.0% increase in Adjusted EBITDA for Q2 2025, demonstrating operational strength.
• Experienced positive same-facility revenue growth of 5.1% and case growth of 3.4% in Q2 2025, indicating healthy organic performance.
• Reaffirmed full-year 2025 revenue and Adjusted EBITDA guidance, signaling confidence in future performance.
• Actively evaluating portfolio optimization opportunities to expedite leverage reduction and accelerate cash flow generation.
• Maintains an optimistic outlook on surgical trends and the regulatory landscape, positioning for continued growth.

Negatives

• Reported a net loss attributable to Surgery Partners, Inc. of $2.5 million for Q2 2025 and $40.2 million year-to-date 2025.
• Cash flows from operating activities decreased to $81.3 million in Q2 2025 from $82.8 million in Q2 2024, primarily due to an increase in cash interest payments.
• Year-to-date operating cash flows decreased to $87.3 million from $123.5 million in the prior year period, driven by higher cash interest payments and timing of changes in working capital.
• The company's leverage calculated using consolidated debt from the balance sheet divided by Adjusted EBITDA was 4.7x times.

Risks

• Reductions in payments from government health care programs and private insurance payors.
• Ability to contract with private insurance payors.
• Changes in payor mix or surgical case mix.
• Failure to maintain or develop relationships with physicians on beneficial or favorable terms.
• Impact of payor controls designed to reduce the number of surgical procedures.
• Efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities.
• Supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies.
• Competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts.
• Ability to attract and retain qualified health care professionals.
• Ability to enforce non-compete restrictions against physicians.
• Ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities.
• Impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on the business.
• Ability to comply with current health care laws and regulations.
• Outcome of legal and regulatory proceedings that have been or may be brought against the company.
• Impact of cybersecurity attacks or intrusions.
• Changes in the regulatory, economic and other conditions of the states where surgical facilities are located.
• Indebtedness.
• The social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on the business.

Future Outlook

The company reaffirmed its full year 2025 revenue guidance of $3.30 billion to $3.45 billion and Adjusted EBITDA guidance of $555 million to $565 million. Management anticipates continued margin expansion, reflecting ongoing operating system improvements, integration benefits from recent acquisitions, and contributions from new de novo facilities expected to open this year. The company is also actively evaluating portfolio optimization opportunities to expedite leverage reduction, accelerate cash flow generation, and provide increased flexibility to self-fund its growth algorithm.

Management Comments

• Eric Evans, CEO: "We are proud to report strong growth in Adjusted EBITDA and revenue, demonstrating the strength of our operational strategy as we capitalize on the continued momentum in the ambulatory surgery industry. Our continued focus on maximizing portfolio performance, optimistic outlook on surgical trends and regulatory landscape, and focus on exceptional clinical quality and value, positions us for continued growth in 2025 and beyond. Our growth is the result of a relentless focus on excellence and differentiation in our core short-stay surgical service lines. In line with our commitment to enhance shareholder value, we are actively evaluating portfolio optimization opportunities to expedite leverage reduction, accelerate cash flow generation and provide increased flexibility to self-fund our growth algorithm following the conclusion of the recent strategic process."
• Dave Doherty, CFO: "The results we report today are very much aligned with our internal expectations and give us confidence in reaffirming our guidance for the full year. Our guidance implies continued margin expansion, reflecting our on-going operating system improvements as well as the integration benefits from recent acquisitions and contributions from de novos we expect to open this year."

Industry Context

The company operates within the ambulatory surgery industry, a sector focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in short-stay facilities. The reported strong growth in revenue and Adjusted EBITDA aligns with the company's strategy to capitalize on the continued momentum in this industry, which is benefiting from broader healthcare trends favoring outpatient settings for efficiency and cost savings.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison to industry standards.

Legal Proceedings

• The non-GAAP reconciliation includes adjustments for 'Litigation settlements and other litigation costs', but no specific ongoing legal proceedings are detailed in the filing.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and Adjusted EBITDA growth, reaffirmed guidance, and commitment to enhance shareholder value through portfolio optimization. Potential concern from net loss and decreased operating cash flow.
• Employees: Continued growth and operational improvements may indicate job stability and potential expansion.
• Customers (Patients): Focus on "exceptional clinical quality and value" suggests continued high-quality care.
• Physicians: Continued focus on maintaining and developing relationships with physicians.
• Creditors: High leverage ratio (4.1x-4.7x) and increased interest payments are relevant, but portfolio optimization aims to expedite leverage reduction.

Next Steps

• Actively evaluating portfolio optimization opportunities to expedite leverage reduction, accelerate cash flow generation, and provide increased flexibility to self-fund growth.
• Expect to open new de novo facilities this year.
• Hold a conference call on August 5, 2025, at 8:30 a.m. (Eastern Time) to discuss results.

Key Dates

Recommendation

While Surgery Partners demonstrated strong revenue and Adjusted EBITDA growth and reaffirmed its full-year guidance, indicating operational strength and confidence, the company also reported a net loss and a decline in operating cash flow, primarily due to higher interest payments. The leverage ratio remains relatively high. The strategic focus on portfolio optimization to reduce debt is a positive, but the current financial structure warrants a cautious approach. An investor might hold to observe the execution of leverage reduction strategies and sustained improvement in cash flow before considering further investment.

Keywords

Surgery Partners, SGRY, healthcare, ambulatory surgery, surgical facilities, earnings, financial results, Q2 2025, EBITDA, revenue, short-stay surgery, healthcare services